Regenicin Stock Current Valuation
| RGIN Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of Regenicin helps investors to measure Regenicin's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Regenicin's price fluctuation is very steady at this time. Calculation of the real value of Regenicin is based on 3 months time horizon. Increasing Regenicin's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Regenicin is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regenicin Pink Sheet. However, Regenicin's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Regenicin's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regenicin's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regenicin helps investors to forecast how Regenicin pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regenicin more accurately as focusing exclusively on Regenicin's fundamentals will not take into account other important factors: Regenicin Company Current Valuation Analysis
Regenicin's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Regenicin Current Valuation | 659.26 K |
Most of Regenicin's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenicin is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Regenicin has a Current Valuation of 659.26 K. This is 100.0% lower than that of the Healthcare sector and 99.99% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Regenicin Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenicin's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regenicin could also be used in its relative valuation, which is a method of valuing Regenicin by comparing valuation metrics of similar companies.Regenicin is currently under evaluation in current valuation category among its peers.
Regenicin Fundamentals
| Return On Asset | -37.38 | |||
| Current Valuation | 659.26 K | |||
| Shares Outstanding | 153.48 M | |||
| Shares Owned By Insiders | 18.15 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (9.70) X | |||
| EBITDA | (655.96 K) | |||
| Net Income | (639.26 K) | |||
| Cash And Equivalents | 2.24 K | |||
| Total Debt | 629.92 K | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (27.29 K) | |||
| Earnings Per Share | (0) X | |||
| Beta | -1.79 | |||
| Market Capitalization | 214.88 K | |||
| Total Asset | 15.49 K | |||
| Retained Earnings | (11.8 M) | |||
| Working Capital | (1.53 M) | |||
| Current Asset | 293 K | |||
| Current Liabilities | 1.83 M | |||
| Net Asset | 15.49 K |
About Regenicin Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenicin's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenicin using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenicin based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Regenicin
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regenicin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regenicin will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Regenicin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regenicin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regenicin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regenicin to buy it.
The correlation of Regenicin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regenicin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regenicin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regenicin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.